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Abstract
Background: Hereditary hemochromatosis (HH) encompasses a group of autosomal recessive disorders mainly
characterized by enhanced intestinal absorption of iron and its accumulation in parenchymal organs. HH diagnosis
is based on iron biochemical and magnetic resonance imaging (MRI) assessment, and genetic testing. Questionnaires,
such as SF-36 (short form health survey), have been increasingly used to assess the impact of diseases on the patient’s
quality of life (QL). In addition, different genotypes are identified as results of genetic tests in patients with suspected
primary iron overload. In the present study, our aim was to evaluate whether domains of QL are different according to
genotypic groups in patients suspected of HH.
Methods: Seventy-nine patients with primary iron overload were included and two genotypic groups were formed
(group 1: homozygous genotype for the HFE p.Cys282Tyr mutation; group 2: other genotypes).
Results: Group 1 had higher means of plasma transferrin saturation (86 ± 19%) and serum ferritin (1669 ± 1209 ng/mL)
compared to group 2 (71 ± 12%, 1252 ± 750 ng/mL, respectively; p = 0.001). Four domains were significantly different
among groups 1 and 2: physical functioning (p = 0.03), bodily pain (p = 0.03), vitality (p = 0.02) and social
functioning (p = 0.01).
Conclusions: Our main finding was that patients with p.Cys282Tyr homozygosity had a worse QL scenario
assessed by SF-36, compared with patients with iron overload without the same genotype. Being aware of
this relationship between genotypes and QL might be helpful in the overall management of patients suspected of
hereditary hemochromatosis.
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Background
Hereditary hemochromatosis (HH) is an autosomal reces-
sive disorder mainly characterized by enhanced intestinal
absorption of iron and its accumulation in parenchymal
organs. The main symptoms of HH are fatigue, skin pig-
mentation, joint pains, impotence, liver signs, diabetes,
and cardiac symptoms [1–4]. HH is classified in 5 types.
Type 1 is related to HFE mutations, especially by
homozygous genotype for the p.Cys282Tyr mutation.
Other HH types are named non-HFE hemochromatosis:
type 2 or juvenile hemochromatosis (JH), sub-divided into
2 forms, type 2A, related with mutations in the HJV gene,
and type 2B, related with mutations in the HAMP gene;
type 3 is related to mutations in the TFR2 gene; and type
4 is related to mutations in the SLC40A1 gene [3, 4].
The diagnosis is essentially based on iron assessment by
laboratory tests, magnetic resonance imaging (MRI), and
genetic testing. p.Cys282Tyr homozygosity in patients
with iron overload is the most frequent finding. However,
other genotypes, such as compound heterozygosity for the
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p.Cys282Tyr/p.His63Asp mutations, heterozygosity or a
negative result for these two genetic variants, can also
be observed in patients with suspected HH iron
overload [5, 6].
Quality of life (QL) is a widely used concept in scientific
research in the fields of economy, education, medicine,
psychology and health sciences. The term QL was firstly
cited in the medical literature in the 30s [7, 8]. According
to the World Health Organization (WHO), QL is “the in-
dividual’s perception of their position in life, in the context
of culture and value systems in which they live and in rela-
tion to their goals, expectations, standards and concerns”
[9]. Generic or specific instruments can assess QL.
Generic instruments evaluate the aspects related with QL
of patients in global or generic forms, while the specific
instruments assess QL in an area of interest, such as a spe-
cific disease, population, condition or situation [10–12].
The short form health survey (SF-36) is a generic and
standardized QL questionnaire. The explored domains
are derived from forty domains of the Medical Outcomes
Study [13]. The SF-36 has several strengths, such as versa-
tility and the small time of administration [13–15]. The
questionnaire was translated and validated in the Portu-
guese language, and adapted culturally for the Brazilian
population [14, 16]. Our hypothesis that QL would differ
according to genotypes is based on the risk of iron over-
load among genotypes. These differences and interpret-
ation of the genotypes were described by European
Molecular Genetics Quality Network (EMQN), an
organization that promote quality in genetic testing
by establishing, harmonizing and disseminating best
practice [2].
Our aim was to explore whether domains of QL, as
evaluated by the SF-36, were different according to
genotypic groups in patients with suspected HH.
Methods
Patients
The study protocol was approved by the Institutional
Ethics Committee of Instituto do Coração - HC-FMUSP
(4027/14/007) and written informed consent was obtained
from all participants prior to entering the study, in com-
pliance with the Helsinki Declaration. Patients were se-
lected from hematology outpatient clinics (Ambulatório
de Hematologia do Hospital das Clínicas - São Paulo,
Ambulatório do Hemocentro da Santa Casa - São Paulo,
and Instituto Naoum de Hematologia - São José do Rio
Preto), Brazil.
The inclusion criteria were: age greater than or equal
to 18 years, transferrin saturation (TS) ≥45% and serum
ferritin (SF) ≥200 ng/mL for females or ≥300 ng/mL for
males. The exclusion criteria were: patients with positive
serology for hepatitis C or B, alcoholic liver disease, high
alcoholic consumption (>20 g daily), hemolytic anemias,
repeated blood transfusions, metabolic syndrome, or in-
sulin resistance not resulting from HH. In this analyzed
casuistic, we also excluded patients with juvenile
hemochromatosis carrying HAMP and HJV mutations
[17, 18].
DNA extraction and genetic testing
Blood was drawn using the BD Vacutainers System®
(Becton Dickinson, NJ, USA) for blood cell count and
genetic analysis. Genomic DNA was isolated from
peripheral blood leukocytes by a salting-out method.
Coding sequences of the HFE exons 2 and 4 were amplified
by polymerase chain reaction (PCR) using the previously
described primer sequences [19]. PCR products were
purified using ExoSAP-IT® reagent (GE Healthcare, NJ,
USA) and were bidirectionally sequenced using the ABI
Terminator Sequencing Kit according to the manufac-
turer’s instructions and an ABI 3500XL Sequencer®
(Applied Biosystems, Foster City, CA, USA).
SF-36 health survey
The questionnaire is based on 36 questions. It is distrib-
uted in eight domains representing the most frequently
evaluated and influenced by diseases and/or treatments,
consisting of physical functioning, role-physical, bodily
pain, general health perception, vitality, social function-
ing, role-emotional and mental health. The values for
each domain range from 0 to 100 points; and higher
scores indicate a better health condition [13–15].
All participants of both groups answered the SF-36
questionnaire once, applied by an interviewer or self-
administered plus reviewed by an interviewer. The ques-
tionnaire was applied after the knowledge of the genotype
by the patient. For each question, fixed values were attrib-
uted and then converted in eight scores (raw scale) for the
domains. Thus, eight values were obtained, one for each
domain. The scoring of SF-36 was performed according to
the instructions of the instrument authors [15].
Statistical analysis
Categorical variables are presented as percentages, while
continuous variables are presented as means ± standard
deviations. Kolmogorov-Smirnov test was used for test-
ing Normality. Chi-square or Fisher tests were per-
formed for the comparative analysis of the categorical
variables (such as gender, self-declared ethnicity, level of
education, and consumption of alcoholic beverages) ac-
cording to the genotypic group. Student’s t-test was used
for comparing mean values of the SF-36 domains, TS
and SF among groups 1 and 2. Mean values of the TS
and SF were adjusted for age and gender. Mean values
of the SF-36 domains were adjusted for age, gender, TS
and SF. The level of significance was set at p ≤ 0.05. All
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statistical analyses were carried out using SPSS software
(v. 16.0).
Results
Seventy-nine patients with primary iron overload were
included. Two genotypic groups were formed: group 1,
patients with primary iron overload and homozygous
genotype for the p.Cys282Tyr mutation (n = 29). And,
group 2, patients with primary iron overload and other ge-
notypes: compound heterozygosity for the p.Cys282Tyr/
p.His63Asp mutation (n = 11), heterozygosity for the
p.Cys282Tyr (n = 4), homozygosity (n = 12) or heterozygos-
ity (n = 9) for the p.His63Asp, or absence of p.Cys282Tyr
or p.His63Asp (n = 14).
Table 1 shows the general characteristics according to
genotypic groups of the patients. Group 1 presented
lower percentage of males (44.8%) and higher means of
TS (86 ± 19%) and SF (1669 ± 1209 ng/mL) compared
with group 2 (84.0%, 71 ± 12%, 1252 ± 750 ng/mL; 0.001,
< 0.001, < 0.001, respectively). We did not observe
significant difference in a comparison of frequency of
the common diseases and of therapy phases among
patient groups.
Table 2 shows the mean values of the SF-36 domains ac-
cording to patient groups. Four domains were significantly
different among groups 1 and 2: physical functioning (p =
0.03), bodily pain (p = 0.03), vitality (p = 0.02) and social
functioning (p = 0.01). Group 1 had lower mean values for
these four domains compared with group 2 (Table 2). In
addition, Additional file 1: Table S1 shows the signs and
symptoms reported by patients according to the genotypic
groups. Group 1 reported greater frequency of signs and
symptoms compared with group 2.
Discussion
The most common, well-defined and prevalent form of
HH is HFE-related HH, associated with homozygosity
for the p.Cys282Tyr. However, there are other
genotypes, which have lower penetrance for HH, that
are relatively frequent in patients with iron overload
[2, 20]. In this study, we defined group 1 as the one
formed by patients carrying homozygous genotypes for
the p.Cys282Tyr mutation and group 2 with patients
carrying other genotypes. Group 1 had lower values for
four domains (physical functioning, bodily pain, vitality
and social functioning) compared with group 2. Therefore,
patients with p.Cys282Tyr homozygosity had worse QL
assessed by SF-36, compared with patients with iron over-
load without the same genotype. Both groups 1 and 2 of
patients with iron overload require therapeutic manage-
ment, but the knowledge of this relationship between
identified genotype and QL might be an interesting infor-
mation for improving the clinical care of the patient,
including physical and social aspects.
Some interesting studies reported the SF-36 use with
HH patients. Meiser et al. studied the difference among
clinically affected and unaffected subjects in a
hemochromatosis clinic in Australia. Thirty participants
were categorized as being clinically affected, and sixty-
six as clinically unaffected. For all domains of SF-36,
clinically unaffected individuals had higher scores than
affected individuals [21]. Van der Plas et al. investigated
patients of the Dutch liver patient association divided
into five groups: hemochromatosis, viral hepatitis, auto-
immune hepatitis, cholestatic liver disease, and other
Table 1 General characteristics according to genotypic groups
of the patients
Group 1a, n = 29 Group 2b, n = 50 p value
Gender (male), % 44.8 84.0 0.001
Age (years), mean ± SD 45 ± 12 49 ± 12 0.14
Transferrin saturation (%),
mean ± SD
86 ± 19 71 ± 12 < 0.001
Serum ferritin (ng/mL),
mean ± SD
1669 ± 1209 1252 ± 750 < 0.001
Self-declared race/color, %
White 82.7 82.0
Intermediate 17.3 12.0 0.35
Others 0 6.0
Level of education, %
University 62.1 68.0 0.77
Others 37.9 32.0
Consumption of alcoholic beverages, %
Never 51.7 36.0
Occasionally 44.8 54.0 0.30
Frequently 3.5 10.0
aGroup 1: patients with primary iron overload and homozygosity for the
p.Cys282Tyr mutation
bGroup 2: patients with primary iron overload and other genotypes:
compound heterozygosity for the p.Cys282Tyr/p.His63Asp (n = 11),
heterozygosity for the p.Cys282Tyr (n = 4), homozygosity (n = 12) or
heterozygosity (n = 9) for the p.His63Asp, or absence of p.Cys282Tyr or and
p.His63Asp (n = 14)
Table 2 Mean (±standard deviation) values of the SF-36 domains
according to genotypic groups of the patients
SF-36 domains Group 1, n = 29 Group 2, n = 50 p value
Physical functioning 78 ± 23 90 ± 14 0.03
Role-physical 75 ± 40 83 ± 31 0.36
Bodily pain 66 ± 25 78 ± 22 0.03
General health perception 62 ± 23 67 ± 14 0.41
Vitality 53 ± 26 67 ± 18 0.02
Social functioning 69 ± 35 85 ± 17 0.01
Role-emotional 77 ± 34 82 ± 31 0.53
Mental health 67 ± 24 74 ± 17 0.18
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liver diseases. They showed that patients with HH had
significantly lower scores in the domain of bodily pain
compared with patients with other etiological groups. In
addition, HH patients had significantly lower scores in
the physical component of all other etiological groups,
except in relation to autoimmune hepatitis [22]. Graaff
et al., using the Assessment of Quality of Life 4D instru-
ment (AQOL-4D), assessed 270 patients with HH that
completed a web-based survey in Australia. This ques-
tionnaire provides a global health state utility value on a
scale from −0.04 to 1.00. The mean utility for all HH
participants was 0.66, lower than the Australian popula-
tion (0.81). In addition, they observed that symptomatic
stages of HH were associated with lower utility than
asymptomatic stages [23]. In contrast to the findings of
the present study and to above-mentioned studies,
Shaheen et al., recruiting 126 HH patients from out-
patient clinics, demonstrated that subjects with HH
reported a QL similar to both unaffected siblings and
general population [24].
In the present study, we observed greater proportion
of males in the group 2 compared with group 1. This
may be related to the known relative protection for iron
overload by menstruations and pregnancies added to
low penetrance associated to genotypes other than non-
p.Cys282Tyr homozygosity. A possible influence of the
high percentage of women in the group 1 on the ob-
served lower scores cannot be excluded [25]. However,
we were able to identify significant findings performing
an adjusted analysis for the covariates age and gender.
In addition, group 1 had higher TS and SF mean values
compared with group 2. Nevertheless, the mean values of
group 2 were also very high, compared with iron parame-
ters in the general population. The observed differences
could be explained by group classification based on the
genotypes. The current interpretation of genotypes and
their influence on iron overload has been detailed by the
EMQN guidelines. p.Cys282Tyr homozygosity is compat-
ible with HFE-related HH in the presence of documented
evidence of iron overload; patients with Cys282Tyr/
p.His63Asp compound heterozygosity may be at-risk of
developing mild to moderate iron overload in association
with comorbid factors (such as metabolic syndrome or
chronic alcoholism); heterozygous p.Cys282Tyr; homozy-
gous p.His63Asp, and heterozygous p.His63Asp carriers
have no increased risk of developing HFE-related HH; are
at no increased risk of developing HFE-related HH.
Testing for the p.S65C variant is not recommended [2].
Our study has some limitations. First, MRI was not
performed for organ iron overload quantification. How-
ever, the inclusion criteria that combined elevated SF
and TS together with exclusion criteria ruling out the
interference of the secondary causes, strongly favor the
diagnosis of primary iron overload in the whole cohort.
Second, we tested only the main mutations in the HFE
gene, thus, we cannot exclude the presence of other mu-
tations in the HFE, HJV (type 2A HH), HAMP (type 2B
HH), TFR2 (type 3 HH), and SLC40A1 (type 4B) genes.
However, there was no patient with JH profile in this
casuistic. Finally, domain differences could not be
related to numerical differences of the signs and
symptoms.
Conclusions
In conclusion, this study mainly shows that patients with
p.Cys282Tyr homozygosity had worse QL scenario
assessed by SF-36, compared with patients with primary
iron overload that do not carry the same genotype. Being
aware of this relationship between genotypes and QL
might be helpful in the overall management of patients
suspected of hereditary hemochromatosis.
Additional file
Additional file 1: Table S1. Signs and symptoms reported by patients
according to genotypic groups. (DOCX 14 kb)
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